Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Benbassat, S. Penchas, M. Ligumski (1979)
Splenectomy in Patients with Agnogenic Myeloid Metaplasia: an Analysis of 321 Published CasesBritish Journal of Haematology, 42
H. Mulder, J. Steenbergen, Clemens Haanen (1977)
Clinical Course and Survival after Elective Splenectomy in 19 Patients with Primary MyelofibrosisBritish Journal of Haematology, 35
P. Donovan, M. Kaplan, J. Goldberg, I. Tatarsky, Y. Najean, E. Silberstein, W. Knospe, J. Laszlo, K. Mack, P. Berk, L. Wasserman (1984)
Treatment of polycythemia vera with hydroxyureaAmerican Journal of Hematology, 17
Schaefer G Budde U (1984)
Acquired von Willebrand's disease in the myeloproliferative disorders.Blood, 64
B. Gordon, M. Coleman, P. Kohen, N. Day (1981)
Immunologic abnormalities in myelofibrosis with activation of the complement system.Blood, 58 5
Maze S Jacobs P (1985)
Myelofibrosis splenectomy and portal hypertension.Acta Haematol, 74
Baraldi A Barosi G (1984)
Polycythaemia following splenectomy in myelofibrosis with myeloid metaplasia.Scand J Haematol, 32
G. Milner, C. Geary, L. Wadsworth, A. Doss (1973)
Erythrokinetic Studies as a Guide to the Value of Splenectomy in Primary Myeloid MetaplasiaBritish Journal of Haematology, 25
Landaw Sa (1976)
Acute leukemia in polycythemia vera.Seminars in hematology, 13 1
Lottenberg R Varki A (1983)
The syndrome of idiopathic myelofibrosis.Medicine, 62
H. Wagner, P. McKeough, J. Desforges, H. Madoc‐Jones (1986)
Splenic irradiation in the treatment of patients with chronic myelogenous leukemia or myelofibrosis with myeloid metaplasia : Results of daily and intermittent fractionation with and without concomitant hydroxyureaCancer, 58
Majarakis JD Cole WH (1955)
Surgical aspects of splenic disease.Arch Surg, 71
Silverstein MN (1983)
Hematology
Nagler A Halpern A (1985)
Post-splenectomy infections in 208 traumatized splenectomized patients.Digestive Surg, 5
E. Besa, P. Nowell, N. Geller, F. Gardner (1982)
Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: The value of chromosomal studies in predicting response and survivalCancer, 49
G. Barosi, A. Baraldi, M. Cazzola, A. Fortunato, P. Palestra, G. Polino, S. Ramella, P. Spriano (2009)
Polycythaemia following splenectomy in myelofibrosis with myeloid metaplasia. A reorganization of erythropoiesis.Scandinavian journal of haematology, 32 1
B. Brenner, S. Tavori, I. Tatarsky (1987)
Influence of splenectomy on hemostasis in agnogenic myeloid metaplasia.Haemostasis, 17 3
McKeough PG Wagner H (1986)
Splenic irradiation in the treatment of patients with chronic myelogenous leukemia or myelofibrosis with myeloid metaplasia.Cancer, 58
M. Silverstein (1974)
Postpolycythemia myeloid metaplasia.Archives of internal medicine, 134 1
C. Magee, G. Rodeheaver, G. Golden, J. Fox, M. Edgerton, R. Edlich (1976)
Potentiation of wound infection by surgical drains.American journal of surgery, 131 5
U. Budde, G. Schaefer, N. Mueller, H. Egli, J. Dent, Z. Ruggeri, T. Zimmerman (1984)
Acquired von Willebrand's disease in the myeloproliferative syndrome.Blood, 64 5
Marcelle Kaplan, K. Mack, Judith Goldberg, P. Donovan, Berk Pd, Louis Wasserman (1986)
Long-term management of polycythemia vera with hydroxyurea: a progress report.Seminars in hematology, 23 3
W. Cole, J. Majarakis, L. Limarzi (1955)
Surgical aspects of splenic disease.A.M.A. archives of surgery, 71 1
H. Taylor (1952)
Chronic non-leukemic myelosis.The Medical journal of Australia, 2 1
Shapiro PF Ivy AC (1935)
The bleeding tendency in jaundice.Surg Gynecol Obstet, 60
A. Varki, R. Lottenberg, R. Griffith, E. Reinhard (1983)
The Syndrome of Idiopathic Myelofibrosis: A CLINICOPATHOLOGIC REVIEW WITH EMPHASIS ON THE PROGNOSTIC VARIABLES PREDICTING SURVIVALMedicine, 62
J. Malmaeus, T. Akre, H. Adami, H. Hagberg (1986)
Early postoperative course following elective splenectomy in haematological diseases: A high complication rate in patients with myeloproliferative disordersBritish Journal of Surgery, 73
Ellis Jt, P. Peterson, Geller Sa, H. Rappaport (1986)
Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies.Seminars in hematology, 23 2
R. ZUNIGA, M. GUTIERREZ (1952)
[Agnogenic myeloid metaplasia].Revista medica de Costa Rica, 11 221
J. Benbassat, S. Penchas (1981)
'Early' splenectomy and survival in agnogenic myeloid metaplasia. An analysis of 338 cases published since 1940.Acta haematologica, 65 3
Hickling RA (1937)
Chronic non-leukemic myelosis.Q J Med, 6
W. Crosby (1972)
Splenectomy in hematologic disorders.The New England journal of medicine, 286 23
A. Schafer (1984)
Bleeding and thrombosis in the myeloproliferative disorders.Blood, 64 1
M. Silverstein, W. Remine (1979)
Splenectomy in myeloid metaplasia.Blood, 53 3
R. Sharon, I. Tatarsky, Y. Ben‐Arieh (1986)
Treatment of polycythemia vera with hydroxyureaCancer, 57
P. Jacobs, S. Maze, F. Tayob, E. Harries‐Jones (1985)
Myelofibrosis, splenomegaly, and portal hypertension.Acta haematologica, 74 1
Abstract • A retrospective analysis of 34 successive splenectomies in 137 patients with myelofibrosis was carried out. Indications, complications, and response to splenectomy were compared between 22 patients with agnogenic myeloid metaplasia (AMM) and 12 patients with postpolycythemic myeloid metaplasia (PPMM). Painful splenomegaly, refractory hemolytic anemia, and refractory thrombocytopenia were the common indications for surgery. The best results were obtained for painful splenomegaly. For the other indications, half to three fourths of the patients improved with splenectomy. An increased incidence of excessive hemorrhage, infected hematoma, and early mortality was more common in the PPMM group and was found to be connected with large spleens, prolonged bleeding time, and prominent thrombocytopenia. Persistent thrombocytosis after surgery was more common in the AMM group. Leukemic transformation seemed to be related to thrombocytosis and to prior therapy with alkylating agents. Median survival following splenectomy was 43 months in the AMM group and 32 months in the PPMM group. We conclude that splenectomy has a role in improving the quality of life by ameliorating mechanical discomfort and decreasing transfusion requirement in the late phase of AMM. However, in patients with PPMM, because of the high complication rate, splenectomy should be carefully considered for specific indications on an individual basis. (Arch Intern Med 1988;148:2501-2505) References 1. Hickling RA: Chronic non-leukemic myelosis. Q J Med 1937;6:253-275. 2. Cole WH, Majarakis JD, Limarzi LR: Surgical aspects of splenic disease. Arch Surg 1955;71:33-46.Crossref 3. Crosby WH: Splenectomy in hematologic disorders. N Engl J Med 1972;286:1252-1256.Crossref 4. Mulder H, Steenbergen J, Haansen C: Clinical course and survival after elective splenectomy in 19 patients with primary myelofibrosis. Br J Haematol 1977;35:419-427.Crossref 5. Silverstein MN, ReMine WH: Splenectomy in myeloid metaplasia. Blood 1979;53:515-518. 6. Varki A, Lottenberg R, Griffith R, et al: The syndrome of idiopathic myelofibrosis. Medicine 1983;62:353-371.Crossref 7. Silverstein MN: Agnogenic myeloid metaplasia , in Williams JW, Beutler E, Erslev AJ, et al (eds): Hematology , ed 3. New York, McGraw-Hill International Book Co, 1983, pp 214-218. 8. Ellis JT, Peterson P, Geller SA, et al: Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies. Semin Hematol 1986;23:144-155. 9. Ivy AC, Shapiro PF, Melnick P: The bleeding tendency in jaundice. Surg Gynecol Obstet 1935;60:781-784. 10. Benbassat J, Penchas S, Ligumski M: Splenectomy in patients with agnogenic myeloid metaplasia: An analysis of 321 published cases. Br J Haematol 1979;42:207-214.Crossref 11. Silverstein MN: Agnogenic Myeloid Metaplasia . Acton, Mass, Publishing Science Group, 1975, pp 109-114. 12. Silverstein MN: Postpolycythemia myeloid metaplasia. Arch Intern Med 1974;134:113-116.Crossref 13. Milner JR, Geary CG, Wadsworth LD, et al: Erythrokinetic studies as a guide to the value of splenectomy in primary myeloid metaplasia. Br J Haematol 1973;25:467-484.Crossref 14. Jacobs P, Maze S, Tayob F, et al: Myelofibrosis splenectomy and portal hypertension. Acta Haematol 1985;74:45-48.Crossref 15. Brenner B, Tavori S, Tatarsky I: Influence of splenectomy on hemostasis in agnogenic myeloid metaplasia. Haemostasis 1987;17:141-146. 16. Budde U, Schaefer G, Mueller N, et al: Acquired von Willebrand's disease in the myeloproliferative disorders. Blood 1984;64:981-985. 17. Magee C, Rodeheaver GT, Golden GT, et al: Potentiation of wound infection by surgical drains. Am J Surg 1976;131:547-549.Crossref 18. Halpern A, Nagler A, Argov S, et al: Post-splenectomy infections in 208 traumatized splenectomized patients. Digestive Surg 1985;5:22-24. 19. Gordon BR, Coleman M, Kohen P, et al: Immunologic abnormalities in myelofibrosis with activation of the complement system. Blood 1981;58:904-910. 20. Malmaeus J, Akre T, Adami HO, et al: Early post-operative course following elective splenectomy in haematological diseases: A high complication rate in patients with myeloproliferative disorders. Br J Surg 1986;73:720-723.Crossref 21. Barosi G, Baraldi A, Cazzola M, et al: Polycythaemia following splenectomy in myelofibrosis with myeloid metaplasia. Scand J Haematol 1984;32:12-18.Crossref 22. Schafer AI: Bleeding and thrombosis in the myeloproliferative disorders. Blood 1984;64:1-12. 23. Landaw SA: Acute leukemia in polycythemia vera. Semin Hematol 1986;23:156-165. 24. Kaplan ME, Mack K, Goldberg JD, et al: Long term management in polycythemia vera with hydroxyurea: A progress report. Semin Hematol 1986;23:167-171. 25. Sharon R, Tatarsky I, Ben-Arieh Y: Treatment of polycythemia vera with hydroxyurea. Cancer 1986;57:718-720.Crossref 26. Benbassat J, Penchas S: 'Early' splenectomy and survival in agnogenic myeloid metaplasia: An analysis of 338 cases published since 1940. Acta Haematol 1981;65:189-192.Crossref 27. Besa EC, Nowell PC, Geller NC, et al: Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: The value of chromosomal studies in predicting response and survival. Cancer 1982;49:308-313.Crossref 28. Wagner H, McKeough PG, Desforges J, et al: Splenic irradiation in the treatment of patients with chronic myelogenous leukemia or myelofibrosis with myeloid metaplasia. Cancer 1986;58:1204-1207.Crossref
Archives of Internal Medicine – American Medical Association
Published: Nov 1, 1988
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.